Neuropore Therapies, Inc., a clinical stage biopharmaceutical company announced today that it has been awarded a grant from The ALS Association to support the preclinical evaluation and development of its leading Toll-Like Receptor 2 (TLR2) antagonist for the treatment of amyotrophic lateral sclerosis.
Report in Scientific Reports, describes the beneficial effects of NPT200-11 on multiple disease relevant endpoints in a transgenic mouse model of Parkinson's disease.
